Ncardia’s ncyte to promote non-human primate cardiomyocytes

Image Credit: Ncardia

Announcement

Ncardia, a known face in stem cell-related solutions for drug safety assessment and discovery, launched ncyte NHP-C vCardiomyocytes, the first ever available ventricular cardiomyocytes at the commercial stage. It is derived from the induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. The new ncyte NHP-C vCardiomyocytes deliver a translational, ethical, and scalable tool especially for cross-species cardiac studies. The innovation has identified the rapid need for physiologically suitable non-human primate (NHP) in vitro models that reduce the dependency rate on live animals for preclinical research.

Ncardia, a potential research and development human Ipsc technology company, serves across North America and Europe. The company has a strong belief in stem cell technology to introduce excellent therapies to the patients quickly. With this launch, it has contributed to the alternatives in the preclinical research sector. Most of the studies avoid experimentation on live animals. For them, Ncyte will be the best option to proceed with effective research. The cardiac safety research will advance through ncyte’s launch.

The need for precision therapy for cardiac conditions has evolved, and so the researchers require advancement and a shift in the options for preclinical research. This fully functional ncyte provides pace for electrophysiological research. The ncyet model is an assay of functional assays that can be established and used, enabling relatable predictions of the drug-induced responses. The team has the potential to create cardiomyocytes from the IPSC that aligns best with nCyte vcardiomyocytes.

With the introduction of ncyte NHP-C vCardiomyocytes, ncardia encourages the scientific group to go ahead with cross-species mechanist studies, enhance predictive modeling of cardiotoxicity, and reduce drug development risk. Alongside advancing and bolstering ethical preclinical practices in connection with the FDA's current animal testing guidance. Ncyte NHP-C vCardiomyocytes provides a functional pure option that nearly acts like human cardiac pharmacology and electrophysiology. The cells allow scalable, ethical, and predictive safety screening throughout the species, contributing to the biotech and pharmaceutical companies in enhancing and improving safer therapies.

Views and statements from the healthcare leader

Divisional chief executive of Ncardia, Jeroen de Groot, said, “Being the only IPSC-based NHP ventricular cardiomyocytes in the sector ncyte NHP-C vcardiomyocytes have leveled up and have raised a new standard for the translational cardiovascular research. They hand over to researchers the capability to conduct direct cross-species comparisons in vitro. Further to enhance cardiotoxicity risk assessment and fulfill FDA’s emerging expectations for diminishing the use of live non-human primates in safety testing.”